The GLP is committed to full transparency. Download and review our Annual Report.

Putting CAR-T cancer therapy ‘on a leash’ could halt deadly runaway immune reactions

| | July 17, 2019

Unlike traditional chemicals, CAR-T cells are living drugs that further proliferate inside the body. While great for replenishing their cancer-killing troops, it comes with the deadly caveat that the cells may go full-on berserk. Once unleashed, there are few ways to control their activity. In some cases, the good guys turn monstrous, releasing chemicals in a cascade that propel the body into immune overdrive. Left uncontrolled, the result is often fatal.

[Recently], a collaboration between the University Hospital in Würzburg, Germany and the Memorial Sloan Kettering Cancer Center in New York found an easy and reliable way to slam on the CAR-T brake. Rather than acting on CAR-T cells, the antidote severs downstream actions of the cells, leaving them in a dormant state that can be re-awakened.

The drug, called dasatinib, essentially puts CAR-T on a leash—one strong enough to stop deadly runaway immune reactions in their tracks. Currently approved for some types of leukemia, dasatinib is an old-school drug with over a decade of history.

Related article:  Project Recode: Can we create synthetic ‘superhero’ human cells immune to viruses, cancer and aging?

“The evaluation and implementation of dasatinib as an on/off control drug in CAR-T cell immunotherapy should be feasible and straightforward,” the authors wrote. 

Read full, original post: Cancer-Killing Living Drug Is Made Safer With a Simple Off Switch

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend